| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.077 | 0.01 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.095 | 0.01 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.092 | 0.01 |
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | -0.09 | 0.01 |
| mRNA | AG-014699 | GDSC1000 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | -0.093 | 0.01 |
| mRNA | FTI-277 | GDSC1000 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | -0.095 | 0.01 |
| mRNA | PDMP | CTRPv2 | pan-cancer | AAC | -0.093 | 0.02 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | 0.29 | 0.02 |